Tussigon® (hydrocodone/homatropine) – Updated Indication, New Boxed Warning

- In January 2017, the FDA approved Tussigon (hydrocodone/homatropine) for the symptomatic relief of cough in adults and children 6 years of age and older.
    - Tussigon was previously approved for this indication without age specifications.
- In line with a recent FDA Drug Safety Communication, Tussigon has a new boxed warning discussing risks from concomitant opioid use with benzodiazepines or other central nervous system depressants.
- Warnings and precautions of Tussigon include respiratory depression, head injury and increased intracranial pressure, acute abdominal conditions, caution in pediatric use, general use, and special risk patients.
- The recommended dose of Tussigon for children 6 to 11 years of age is one-half tablet every 4 to 6 hours as needed, not to exceed three tablets in 24 hours.
- The recommended dose of Tussigon for adults and adolescents 12 years of age and older is one tablet every 4 to 6 hours as needed, not exceed six tablets in 24 hours.
- Tussigon is a Schedule II controlled substance.